Safety and Immunogenicity Study of GSK Biologicals' Pneumococcal Vaccine 2830930A When Administered as a Single Dose in Healthy Toddlers Aged 12-23 Months.
Phase of Trial: Phase I
Latest Information Update: 19 May 2017
At a glance
- Drugs Pneumococcal vaccine conjugate (Primary) ; Pneumococcal 10-valent vaccine conjugate
- Indications Pneumococcal infections
- Focus Adverse reactions
- Sponsors GlaxoSmithKline
- 06 Apr 2012 Actual patient number 61 added as reported by ClinicalTrials.gov.
- 30 Mar 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 23 Feb 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.